Article
The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation.
Biological research - 19 Feb 2026
Martin-Martin Antonia, Chipón Carina, Guzman-Kunstmann Constanza, Guzman-Kunstmann Sergio, Buelvas Neudo, Henríquez Claudio, Vidal Francisca, Villarroel-Espindola Franz, Hinz Trista K, Heasley Lynn E, López-Muñoz Rodrigo A
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for most lung cancer cases and poses major challenges due to late-stage diagnosis and limited options. A substantial subset of NSCLC harbors KRAS mutations, most commonly at codon 12. Although KRASG12C inhibitors show clinical activity, their efficacy is frequently limited by acquired resistance. Polyamines (putrescine, spermidine, and spermine) regulate key...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.